Imprint
Christoph Thomssen, Karl-Friedrich Bürrig, Halit Yilmaz, Andreia Albuquerque(Universidade do Porto), Athanasios Vergopoulos(University Hospital Zurich), Varol Çelik, Michael J. Knauer(Western University), Bernhard Holland, Markus Fahrni, Florian Fitzal, Christoph Uleer, Andreas Trojan(Immunologie-Zentrum Zürich), Ali Çerçel, Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), R. Huch(Kantonsspital Baden), Erman Aytaç, Thomas Decker, Urs Breitenstein, Norbert Marschner(University Medical Center Freiburg), Christoph Rageth(Hôpital Beau-Séjour), Sylvia Stadlmann, Esther I. Schwarz(MRC Laboratory of Molecular Biology), Volkan Özben(Acıbadem University), Georg Breier(University Hospital Carl Gustav Carus), Nik Hauser(Hirslanden Klinik Aarau), Susanna Hegewisch‐Becker, Anton Scharl, Jasmin Yazdan-Pourfard, Beat Thürlimann(University of St.Gallen), Hans‐Joachim Lück, Wolfgang Jöechle, Hans Tesch, Gad Singer(Kantonsspital Baden), Peter Dubsky(Hirslanden Klinik St. Anna), Georg Pfeiler(Medical University of Vienna), N. Fersis(Klinikum Chemnitz), Andreas Schneeweiß(German Cancer Research Center), Fatih Aydoğan, Anja Welt, Günther Steger(Barwon Health), Christian Jackisch, Gϋnter von Minckwitz(German Breast group), Sepp Kaul, Wolfgang Janni(Universität Ulm), Petra Krabisch(Klinikum Chemnitz), Burkhardt Seifert(Omega Consult (Slovenia)), Nadia Harbeck, Michael Untch(Helios Kliniken)
Cited by 0
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
|Nature|1996|4.2k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k